General Information


We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Our lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of FGF21, is currently being developed for the treatment of NASH. NASH is a severe form of NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, HCC and death. There are currently no approved products for the treatment of NASH. FGF21 is a clinically-validated mechanism that has been shown in humans to reduce steatosis and address cardio-metabolic dysregulation.

Employees: 14
Founded: 2018
Contact Information
Address 535 Mission Street, 14th Floor, San Francisco, CA 94105, US
Phone Number (415) 500-4614
Web Address http://www.89bio.com
View Prospectus: 89bio
Financial Information
Market Cap $207.9mil
Revenues $0 mil (last 12 months)
Net Income $-28.2 mil (last 12 months)
IPO Profile
Symbol ETNB
Exchange NASDAQ
Shares (millions): 5.3
Price range $16.00 - $16.00
Est. $ Volume $84.9 mil
Manager / Joint Managers BofA Securities/ SVB Leerink/ RBC Capital Markets
CO-Managers Oppenheimer & Co.
Expected To Trade: 11/11/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change